NO992116L - Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner - Google Patents

Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner

Info

Publication number
NO992116L
NO992116L NO992116A NO992116A NO992116L NO 992116 L NO992116 L NO 992116L NO 992116 A NO992116 A NO 992116A NO 992116 A NO992116 A NO 992116A NO 992116 L NO992116 L NO 992116L
Authority
NO
Norway
Prior art keywords
therapeutic
cytokines
diagnostic agents
signal transduction
present
Prior art date
Application number
NO992116A
Other languages
English (en)
Norwegian (no)
Other versions
NO992116D0 (no
Inventor
Douglas J Hilton
Warren S Alexander
Elizabeth M Viney
Tracy A Willson
Rachael T Richardson
Robyn Starr
Sandra E Nicholson
Donald Metcalf
Nicos A Nicola
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO3384A external-priority patent/AUPO338496A0/en
Priority claimed from AUPO5117A external-priority patent/AUPO511797A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Publication of NO992116D0 publication Critical patent/NO992116D0/no
Publication of NO992116L publication Critical patent/NO992116L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO992116A 1996-11-01 1999-04-30 Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner NO992116L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO3384A AUPO338496A0 (en) 1996-11-01 1996-11-01 Therapeutic and diagnostic agents
AUPO5117A AUPO511797A0 (en) 1997-02-14 1997-02-14 Therapeutic and diagnostic agents-II
PCT/AU1997/000729 WO1998020023A1 (en) 1996-11-01 1997-10-31 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines

Publications (2)

Publication Number Publication Date
NO992116D0 NO992116D0 (no) 1999-04-30
NO992116L true NO992116L (no) 1999-06-29

Family

ID=25645307

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992116A NO992116L (no) 1996-11-01 1999-04-30 Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner

Country Status (13)

Country Link
US (1) US20080166730A1 (da)
EP (2) EP1975234A2 (da)
JP (2) JP2001502183A (da)
KR (2) KR20000053017A (da)
CN (2) CN101280305A (da)
AT (1) ATE398136T1 (da)
CA (1) CA2270171A1 (da)
DE (1) DE69738767D1 (da)
DK (1) DK0948522T3 (da)
ES (1) ES2308785T3 (da)
GB (1) GB2331753A (da)
NO (1) NO992116L (da)
WO (1) WO1998020023A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
EP0877030A3 (en) * 1997-05-07 2001-05-23 Smithkline Beecham Corporation EPO primary response gene 1,(EPRG1)
WO1999003994A1 (en) * 1997-07-18 1999-01-28 Schering Corporation Suppressors of cytokine signaling socs16; related reagents
WO1999023220A1 (en) * 1997-11-03 1999-05-14 Incyte Pharmaceuticals, Inc. Suppressor of cytokine signaling
WO1999040946A2 (en) * 1998-02-11 1999-08-19 Beth Israel Deaconess Medical Center Methods and compositions for modulating leptin activity
JP2002507418A (ja) * 1998-03-23 2002-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー サイトカインシグナル伝達のサプレッサー
EP0953636A3 (en) 1998-03-23 2000-03-29 Smithkline Beecham Plc Cytokine signal regulators
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
AU4202699A (en) * 1998-05-28 1999-12-13 Incyte Pharmaceuticals, Inc. Human socs proteins
SE9803398D0 (sv) * 1998-10-06 1998-10-06 Sahltech Ab "New use"
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
WO2000063357A2 (en) * 1999-04-20 2000-10-26 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
AU784277B2 (en) * 1999-11-16 2006-03-02 Walter And Eliza Hall Institute Of Medical Research, The An animal model for studying hormone signalling and method of modulating the signalling
CA2390555A1 (en) * 1999-11-16 2001-05-25 The Walter And Eliza Hall Institute Of Medical Research An animal model for studying hormone signalling and method of modulating the signalling
AU2001251612A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2425194A1 (en) * 2000-10-09 2002-04-18 Andrew Nash Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
GB2373502A (en) * 2000-11-08 2002-09-25 Smithkline Beecham Corp Suppressor of cytokine signalling 4 (SOCS4)
AU2002243250A1 (en) * 2000-12-14 2002-07-24 Pharmacia And Upjohn Company Socs (suppressor of cytokine signaling)
AUPR556601A0 (en) * 2001-06-08 2001-07-12 Ludwig Institute For Cancer Research Therapeutic and diagnostic molecules - II
EP1486562A1 (en) * 2002-02-27 2004-12-15 Genox Research, Inc. Method of examining allergic disease
US8420096B2 (en) 2004-03-04 2013-04-16 Vanderbilt University Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling
JP2005312364A (ja) * 2004-04-28 2005-11-10 Mitsuo Itakura 糖尿病治療剤スクリーニング方法
US20090030179A1 (en) * 2005-02-15 2009-01-29 Toagosei Co., Ltd Antimicrobial peptide and use thereof
EP2427210A4 (en) * 2009-05-08 2012-10-24 Inst Medical W & E Hall MODULATION OF INDUCIBLE NITRIC OXIDE BINDING (INOS) TO SOCS-BOX (SSB) PEPTIDES CONTAINING SPRY DOMAINS
KR101124622B1 (ko) * 2009-10-26 2012-03-19 한국생명공학연구원 Ｓｏｃｓ２ 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법
CN112972492B (zh) * 2015-12-16 2024-11-08 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420782C1 (de) * 1994-06-15 1995-08-17 Fluegge Ulf Ingo Prof Dr DNA-Sequenz, kodierend einen 2-Oxoglutarat/Malat-Translokator, Plasmide, Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
CA2143491C (en) * 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
EP0832117A1 (en) * 1995-06-05 1998-04-01 The Trustees Of Dartmouth College Ligand-stimulated gene expression
US6514725B1 (en) * 1997-01-10 2003-02-04 Tadamitsu Kishimoto STAT function-regulatory protein
WO1999003994A1 (en) * 1997-07-18 1999-01-28 Schering Corporation Suppressors of cytokine signaling socs16; related reagents

Also Published As

Publication number Publication date
EP0948522A4 (en) 2001-09-19
NO992116D0 (no) 1999-04-30
WO1998020023A1 (en) 1998-05-14
CN1253565A (zh) 2000-05-17
JP2009060903A (ja) 2009-03-26
KR100719080B1 (ko) 2007-05-16
KR20000053017A (ko) 2000-08-25
GB2331753A (en) 1999-06-02
JP2001502183A (ja) 2001-02-20
EP1975234A2 (en) 2008-10-01
KR20060053007A (ko) 2006-05-19
DE69738767D1 (de) 2008-07-24
ATE398136T1 (de) 2008-07-15
ES2308785T3 (es) 2008-12-01
GB9905020D0 (en) 1999-04-28
DK0948522T3 (da) 2008-09-22
EP0948522B1 (en) 2008-06-11
US20080166730A1 (en) 2008-07-10
CN101280305A (zh) 2008-10-08
EP0948522A1 (en) 1999-10-13
CA2270171A1 (en) 1998-05-14

Similar Documents

Publication Publication Date Title
NO992116L (no) Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner
DE69939864D1 (de) Ppar-gamma modulatoren
DE59005097D1 (de) Verwendung härtbarer Cycloaliphaten-Derivate in Dübelmassen.
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
NO975716L (no) Imidazolforbindelser
DK0850307T3 (da) Alkalifile og termofile mikroorganismer og enzymer, der opnås derfra
DK0804163T3 (da) Forbedret fremgangsmåde til stabilisering af biologiske stoffer under tørring og efterfølgende opbevaring samt præparater deraf
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
ATE234092T1 (de) 2-alkylpyrrolidine
ATE423788T1 (de) Neues tgf-beta-ahnliches cytokin
DE69434209D1 (de) REGULATION DER GENEXPRESSION VON bcl-2
EA200700469A1 (ru) Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
MY107573A (en) 2,4- and 2, 5-substituted pyridine-n-oxides, processes for their preparation and their use.
BG101002A (bg) Заместени арилалкилтио-алкилтиопиридини и използване за борба с бактерии от рода helicobacter
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
ATE433458T1 (de) Modulatoren von ship-1
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
IS2889B (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
ATE255594T1 (de) Hepatitis b inhibitoren
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DK0950056T3 (da) N-(pyridinylamino)isoindoliner og beslægtede forbindelser
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.